Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC
NCT03333343Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2018
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of nazartinib in non-small cell lung cancer (NSCLC) (10 arms), sponsored by Novartis. Primary endpoints: Number of patients with adverse events and serious adverse events at 4 years, Number of participants with Dose-Limiting Toxicities at 28 days and 3 more. Started Jan 2018; status: active, not recruiting.
02
Drugs
nazartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03333343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333343.